Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 - a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  • Patrick Sulzgruber
  • Sven Wassmann
  • Anne Grete Semb
  • Wolfram Doehner
  • Petr Widimsky
  • Thomas Gremmel
  • Juan Carlos Kaski
  • Gianluigi Savarese
  • Giuseppe M C Rosano
  • Claudio Borghi
  • Keld Kjeldsen
  • Christian Torp-Pedersen
  • Thomas Andersen Schmidt
  • Basil S Lewis
  • Heinz Drexel
  • Juan Tamargo
  • Dan Atar
  • Stefan Agewall
  • Alexander Niessner
Vis graf over relationer

Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

OriginalsprogEngelsk
Artikelnummerpvz016
TidsskriftEuropean heart journal. Cardiovascular pharmacotherapy
Vol/bind5
Udgave nummer3
Sider (fra-til)171-180
Antal sider10
ISSN2055-6837
DOI
StatusUdgivet - 1 jul. 2019

ID: 57230123